HONG KONG – South Korean biotech company Samsung Bioepis Co. Ltd. has entered a licensing agreement with China's 3Sbio Inc. to expand its biosimilars business to mainland China. The agreement covers multiple biosimilar candidates from the Incheon-based Samsung Bioepis, including SB-8, a biosimilar to blockbuster anti-VEGF antibody Avastin (bevacizumab, Genentech Inc./Roche Holding AG) that is undergoing phase III trials.